Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Romano

Showing results (421-430 of 435) with videos related to

Pageof 44
Sort By:
Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine|January 17, 2020
The Canadian Medical Student Ultrasound Curriculum: A Statement From the Canadian Ultrasound Consensus for Undergraduate Medical Education GroupIrene W Y Ma, Peter Steinmetz, Kirstin Weerdenburg, et al.
Journal of the American Chemical Society|March 15, 2008
Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A proteaseNigel J Liverton, M Katharine Holloway, John A McCauley, et al.
Journal of Medicinal Chemistry|April 2, 2004
NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazolesJohn A McCauley, Cory R Theberge, Joseph J Romano, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma ExposureMichael T Rudd, John A McCauley, John W Butcher, et al.
Journal of Medicinal Chemistry|February 19, 2010
Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitorJohn A McCauley, Charles J McIntyre, Michael T Rudd, et al.
Bioorganic & Medicinal Chemistry Letters|October 23, 2012
Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkersMichael T Rudd, Charles J McIntyre, Joseph J Romano, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2012
Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A proteaseMichael T Rudd, John A McCauley, Joseph J Romano, et al.
Chemmedchem|March 12, 2015
P2-quinazolinones and bis-macrocycles as new templates for next-generation hepatitis C virus NS3/4a protease inhibitors: discovery of MK-2748 and MK-6325Michael T Rudd, John W Butcher, Kevin T Nguyen, et al.
Journal of Medicinal Chemistry|July 3, 2019
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[<i>d</i>]thiazol-5-ylamino)-6-(<i>tert</i>-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory DiseasesPamela A Haile, Linda N Casillas, Bartholomew J Votta, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease InhibitorSteven Harper, John A McCauley, Michael T Rudd, et al.
Pageof 44

Showing results (421-430 of 435) with videos related to

Sort By:
Pageof 44
Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine|January 17, 2020
The Canadian Medical Student Ultrasound Curriculum: A Statement From the Canadian Ultrasound Consensus for Undergraduate Medical Education GroupIrene W Y Ma, Peter Steinmetz, Kirstin Weerdenburg, et al.
Journal of the American Chemical Society|March 15, 2008
Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A proteaseNigel J Liverton, M Katharine Holloway, John A McCauley, et al.
Journal of Medicinal Chemistry|April 2, 2004
NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazolesJohn A McCauley, Cory R Theberge, Joseph J Romano, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma ExposureMichael T Rudd, John A McCauley, John W Butcher, et al.
Journal of Medicinal Chemistry|February 19, 2010
Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitorJohn A McCauley, Charles J McIntyre, Michael T Rudd, et al.
Bioorganic & Medicinal Chemistry Letters|October 23, 2012
Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkersMichael T Rudd, Charles J McIntyre, Joseph J Romano, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2012
Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A proteaseMichael T Rudd, John A McCauley, Joseph J Romano, et al.
Chemmedchem|March 12, 2015
P2-quinazolinones and bis-macrocycles as new templates for next-generation hepatitis C virus NS3/4a protease inhibitors: discovery of MK-2748 and MK-6325Michael T Rudd, John W Butcher, Kevin T Nguyen, et al.
Journal of Medicinal Chemistry|July 3, 2019
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[<i>d</i>]thiazol-5-ylamino)-6-(<i>tert</i>-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory DiseasesPamela A Haile, Linda N Casillas, Bartholomew J Votta, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease InhibitorSteven Harper, John A McCauley, Michael T Rudd, et al.
Pageof 44